These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35613589)

  • 1. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.
    Anami Y; Otani Y; Xiong W; Ha SYY; Yamaguchi A; Rivera-Caraballo KA; Zhang N; An Z; Kaur B; Tsuchikama K
    Cell Rep; 2022 May; 39(8):110839. PubMed ID: 35613589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
    Marin BM; Porath KA; Jain S; Kim M; Conage-Pough JE; Oh JH; Miller CL; Talele S; Kitange GJ; Tian S; Burgenske DM; Mladek AC; Gupta SK; Decker PA; McMinn MH; Stopka SA; Regan MS; He L; Carlson BL; Bakken K; Burns TC; Parney IF; Giannini C; Agar NYR; Eckel-Passow JE; Cochran JR; Elmquist WF; Vaubel RA; White FM; Sarkaria JN
    Neuro Oncol; 2021 Dec; 23(12):2042-2053. PubMed ID: 34050676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.
    Jain S; Griffith JI; Porath KA; Rathi S; Le J; Pasa TI; Decker PA; Gupta SK; Hu Z; Carlson BL; Bakken K; Burgenske DM; Feldsien TM; Lefebvre DR; Vaubel RA; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
    Clin Cancer Res; 2024 Aug; 30(15):3287-3297. PubMed ID: 38743766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
    Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
    Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
    Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
    J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic warhead-armed antibody for targeted treatment of glioblastoma.
    Xi J; Liu K; Peng Z; Dai X; Wang Y; Cai C; Yang D; Yan C; Li X
    Crit Rev Oncol Hematol; 2024 Jan; 193():104205. PubMed ID: 38036153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drug conjugates for glioblastoma: current progress towards clinical use.
    Gan HK; Parakh S; Osellame LD; Cher L; Uccellini A; Hafeez U; Menon S; Scott AM
    Expert Opin Biol Ther; 2023; 23(11):1089-1102. PubMed ID: 37955063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves
    Nessler I; Khera E; Vance S; Kopp A; Qiu Q; Keating TA; Abu-Yousif AO; Sandal T; Legg J; Thompson L; Goodwin N; Thurber GM
    Cancer Res; 2020 Mar; 80(6):1268-1278. PubMed ID: 31941698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Solid Tumor Treatment with Antibody-drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class.
    Calopiz MC; Linderman JJ; Thurber GM
    Pharm Res; 2024 Jun; 41(6):1109-1120. PubMed ID: 38806889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug conjugate-based anticancer therapy - Current status and perspectives.
    Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
    Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
    Mair MJ; Bartsch R; Le Rhun E; Berghoff AS; Brastianos PK; Cortes J; Gan HK; Lin NU; Lassman AB; Wen PY; Weller M; van den Bent M; Preusser M
    Nat Rev Clin Oncol; 2023 Jun; 20(6):372-389. PubMed ID: 37085569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basics and Innovations in Antibody-Drug Conjugates].
    Manabe S
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):681-685. PubMed ID: 39191680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
    Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
    Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer.
    Moore EJ; Rice M; Roy G; Zhang W; Marelli M
    Xenobiotica; 2024 Aug; 54(8):469-491. PubMed ID: 39329289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.